Literature DB >> 23552980

[Long-term data from the CYCLOPS study].

M Haubitz1.   

Abstract

Mesh:

Substances:

Year:  2013        PMID: 23552980     DOI: 10.1007/s00393-012-1125-2

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


× No keyword cloud information.
  4 in total

1.  Maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.

Authors:  Jan-Stephan F Sanders; Marjan C Slot; Coen A Stegeman
Journal:  N Engl J Med       Date:  2003-11-20       Impact factor: 91.245

2.  Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.

Authors:  Kirsten de Groot; Lorraine Harper; David R W Jayne; Luis Felipe Flores Suarez; Gina Gregorini; Wolfgang L Gross; Rashid Luqmani; Charles D Pusey; Niels Rasmussen; Renato A Sinico; Vladimir Tesar; Philippe Vanhille; Kerstin Westman; Caroline O S Savage
Journal:  Ann Intern Med       Date:  2009-05-19       Impact factor: 25.391

3.  Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study.

Authors:  M Haubitz; S Schellong; U Göbel; H J Schurek; D Schaumann; K M Koch; R Brunkhorst
Journal:  Arthritis Rheum       Date:  1998-10

4.  Histological and clinical predictors of early and late renal outcome in ANCA-associated vasculitis.

Authors:  Irmgard Neumann; Renate Kain; Heinz Regele; Afschin Soleiman; Sandra Kandutsch; Franz Thomas Meisl
Journal:  Nephrol Dial Transplant       Date:  2004-11-16       Impact factor: 5.992

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.